Clin Nutr ESPEN
March 2025
Background & Aims: Medical nutrition therapy (MNT) is commonly used in patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) undergoing intensive remission-induction treatment to prevent malnutrition, particularly the loss of fat-free mass (FFM)/muscle mass, as well as associated adverse outcomes. However, studies examining the associations between proactive versus wait-and-see approaches toward MNT and nutritional, physical, and clinical outcomes in these patients are lacking. Therefore, this study aimed to explore the associations between these different MNT approaches and body composition changes, as well as physical and clinical outcomes in AML/MDS patients undergoing intensive remission-induction treatment.
View Article and Find Full Text PDFBackground/objectives: Patients with acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS) often receive medical nutrition therapy (MNT) during intensive remission-induction treatment. Since little is known about changes in nutritional status, specifically body composition, in this patient population, these changes and their associations with physical and clinical outcomes were assessed.
Subjects/methods: In this multicenter prospective observational study, newly diagnosed AML/MDS patients who received intensive remission-induction chemotherapy, routine dietary counseling by a dietician and MNT immediately upon inadequate nutritional intake, were included.